Expecting $19 Million Cash Income FREMONT, CA - March 19, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ...

Since 2023, ABVC has executed three global licensing agreements valued at $959 million, structured with upfront payments, milestone-based revenues, and commercialization royalties. These agreements ...

在过渡期间，ABVC BioPharma的首席执行官（CEO）Uttam Patil将同时承担CFO的职责。公司未说明Chow先生辞职的具体原因，但确认这一人事变动即刻生效。在公司面临市场挑战之际发生了这一领导层变动，过去十二个月公司收入下降31%。

Over $100 Million Invested in the U.S. FREMONT, CA - March 5, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments ...

Detailed price information for Abvc Biopharma Inc (ABVC-Q) from The Globe and Mail including charting and trades.

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company ...

FREEMONT, CALIFORNIA - February 20, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ABVC BioPharma, Inc. (NASDAQ:ABVC – Get Free Report) shares were up 0.4% on Friday .The company traded as high as $0.66 and last traded at $0.64. Approximately 199,668 shares traded hands during ...

FREMONT, CA - March 5, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central ...

ABVC BioPharma, Inc. (NASDAQ:ABVC), a pharmaceutical company based in Fremont, California, with a market capitalization of $7.79 million, disclosed the departure of its Chief Financial Officer ...